Suchergebnisse - "Conteduca, Vincenza"

PubPharm (197)

1

Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors : A Systematic Review and Meta-Analysis

enthalten in: JAMA network open | 2024

von Maiorano, B. | Di Maio, M. | Cerbone, L. | +104

2

Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer : Results from the Meet-URO 10 Study

enthalten in: European urology open science | 2024

von Casadei, C. | Scarpi, E. | Conteduca, V. | +18

3

Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care

enthalten in: Prostate cancer and prostatic diseases | 2024

von Conteduca, V. | Di Tullio, P. | Allamprese, R. | +21

4

Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes : A Systematic Review and Safety Meta-analysis

enthalten in: Targeted oncology | 2024

von Maiorano, B. | De Giorgi, U. | Verzoni, E. | +5

ErratumIn: Target Oncol. 2023 Dec 9;:. - PMID 38070004

5

Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma : insights from the RELIEVE study's analysis of heavily pretreated patients

enthalten in: Therapeutic advances in urology | 2024

von Buti, S. | Olivari, A. | Masini, C. | +20

6

Correction to : Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis

enthalten in: Targeted oncology | 2024

von Maiorano, B. | De Giorgi, U. | Verzoni, E. | +5

ErratumFor: Target Oncol. 2024 Jan;19(1):1-11. - PMID 37993604

7

Personalized medicine for metastatic prostate cancer : The paradigm of PARP inhibitors

enthalten in: Critical reviews in oncology/hematology | 2023

von Maiorano, B. | Conteduca, V. | Catalano, M. | +4

8

SIUrO best practice recommendations to optimize BRCA 1/2 gene testing from DNA extracted from bone biopsy in mCRPC patients (BRCA Optimal Bone Biopsy Procedure : BOP)

enthalten in: Virchows Archiv : an international journal of pathology | 2023

von Cimadamore, A. | Rescigno, P. | Conteduca, V. | +8

9

Author Correction : Evolution of structural rearrangements in prostate cancer intracranial metastases

enthalten in: NPJ precision oncology | 2023

von Khani, F. | Hooper, W. | Wang, X. | +15

ErratumFor: NPJ Precis Oncol. 2023 Sep 13;7(1):91. - PMID 37704749

10

Immunogenomic profiles associated with response to life-prolonging agents in prostate cancer

enthalten in: British journal of cancer | 2023

von Conteduca, V. | Brighi, N. | Schepisi, G. | +1

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[20]